A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1941-1946

  Niitsu, N ^a,b   Nakamine, H ^b   Okamoto, M ^b   Tamaru, J I ^b   Hirano, M ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group ALTSG   (Japan)

Author keywords

Classical Hodgkin's lymphoma; EBER; nm23 H1; TIA 1

Indexed keywords

BLEOMYCIN; CD15 ANTIGEN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE A; PREDNISOLONE; PROCARBAZINE; T CELL INTRACELLULAR ANTIGEN 1; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; VIRUS RNA;

ADULT; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; REED-STERNBERG CELLS; SURVIVAL RATE;

EID: 54949149195     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn413     Document Type: Article

References (16)

1. Aoki R, Karube K, Sugita Y et al. Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001-2006. Pathol Int 2008; 58: 174-182.
2. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 19: 1478-1484.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
4. Niitsu N, Okabe-Kado J, Kasukabe T et al. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 1999; 94: 3541-3550.
5. Niitsu N, Okabe-Kado J, Okamoto M et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood 2001; 97: 1202-1210.
6. Niitsu N, Nakamine H, Okamoto M et al. Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clin Cancer Res 2004; 10; 2482-2490.
7. Niitsu N, Okamoto M, Tomita N et al. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1908-1914.
8. Homing SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996; 7 (Suppl 4): 105-108.
9. Asano N, Oshiro A, Matsuo K et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinlcopathologic study. J Clin Oncol 2006; 24: 4626-4633.
10. Shresta. S, Pham CT, Thomas DA et al. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10: 581-587.
11. Felgar RE, Macon WR, Kinney MC et al. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997; 150: 1893-1900.
12. Niitsu N, Nakamine H, Okamoto M et al. Adult Lymphoma Treatment Study Group, ALTSG. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 2003; 123: 621-630.
13. Keegan TH, Glaser SL, Clarke CA et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J Clin Oncol 2005; 23: 7604-7613.
14. Herling M, Rassidakis GZ, Vassilakopoulos TP et al. Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma, Blood 2006; 107: 1240; author reply 1241.
15. Steeg PS, Bevilacqua G, Kopper L et al. Evidence for a novel gene associated with low tumor metastatic potential. J Nat Cancer Inst 1988; 80: 200-204.
16. De La Rose A, Williams RL, Steeg PS. Nm23/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions. BioEssays 1995; 17: 53-62.